Costa Eliesse Pereira, Samoel Gisele Vaz Aguirre, Rosa Gilneia da, Osmari Vanessa, Souza Michelli Lopes de, Lopes Luís Felipe Dias, Vogel Fernanda Silveira Flôres, Botton Sônia de Avila, Sangioni Luís Antônio
Programa de Pós-graduação em Medicina Veterinária, Laboratório de Doenças Parasitárias, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria - UFSM, Santa Maria, RS, Brasil.
Departamento de Ciências Administrativas, Universidade Federal de Santa Maria - UFSM, Santa Maria, RS, Brasil.
Rev Bras Parasitol Vet. 2025 Jan 13;34(1):e014824. doi: 10.1590/S1984-29612025001. eCollection 2025.
This study evaluated dynamics of antibodies in dogs treated for canine visceral leishmaniasis (CVL). Twenty-one dogs naturally infected by Leishmania spp. were grouped based on the treatment protocol: G1 (n=4) received allopurinol; G2 (n=10) allopurinol with miltefosine; and G3 (n=7) allopurinol, miltefosine and Leish-Tec® vaccine. The dogs were monitored monthly for a period of one year. To verify serum antibody titers, an indirect immunofluorescence reaction was performed. We found that dogs from G1 and G2 had lower clinical scores and antibody titers, when compared to the parameters evaluated in pre-treatment; however, clinical relapses were observed in three animals. In G3, clinical scores were lower than pre-treatment; however, they presented relatively stable antibody titers and no clinical relapse was observed. All animals submitted to the evaluated treatment protocols showed relative improvement in clinical signs. Furthermore, the immune response of animals must be considered, given the challenges of parasitic loads in infections. Therefore, it is necessary to complement the methods of clinical and therapeutic monitoring of dogs with CVL in order to establish the risk of transmissibility of the agent in infected and treated dogs.
本研究评估了接受犬内脏利什曼病（CVL）治疗的犬只体内抗体的动态变化。21只自然感染利什曼原虫属的犬只根据治疗方案分组：G1组（n = 4）接受别嘌呤醇治疗；G2组（n = 10）接受别嘌呤醇与米替福新联合治疗；G3组（n = 7）接受别嘌呤醇、米替福新及Leish-Tec®疫苗治疗。对犬只进行为期一年的每月监测。为检测血清抗体滴度，进行了间接免疫荧光反应。我们发现，与治疗前评估的参数相比，G1组和G2组的犬只临床评分和抗体滴度较低；然而，有3只动物出现了临床复发。在G3组中，临床评分低于治疗前；然而，它们的抗体滴度相对稳定，未观察到临床复发。所有接受评估治疗方案的动物临床症状均有相对改善。此外，鉴于感染中寄生虫负荷带来的挑战，必须考虑动物的免疫反应。因此，有必要补充CVL犬只的临床和治疗监测方法，以确定感染和治疗犬只中病原体的传播风险。
